Social Media Ideas for Abbvie

Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year

AbbVie has another blockbuster business emerging.

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

AbbVie Seeks Block On Alkem Generic Constipation Drug

AbbVie Inc. and collaborator Ironwood Pharmaceuticals urged a New Jersey federal court to bar India-based generic drugmaker Alkem Laboratories from selling generic versions of thei...

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

The pharmaceutical company hopes that another big-time acquisition will pay off.

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?

AbbVie 'Concocted' Cancer Drug IP Claims, Biotech Firm Says

Biotech firms ProfoundBio and Genmab urged a Seattle federal judge Thursday to throw out rival AbbVie's lawsuit accusing two of its former employees of taking trade secrets on canc...

3 Reasons to Buy AbbVie Stock Like There's No Tomorrow

It looks like a great buy-and-hold option.

How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?

There's no need to panic.

Should You Buy AbbVie Stock Hand Over Fist Before July 31?

The recent rally could pave the way for "sell the news" volatility, but don't let this scare you out of a long-term position.

AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial

AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates and progression-free survival in patients with relapsed/...

<![CDATA[M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration wit...

Companies join forces to commercialize proposed biosimilar

Alvotech and Lotus Pharmaceutical are teaming up on plans to commercialize AVT87, a proposed biosimilar to Hemlibra (emicizumab). Lisa Graver, CEO of Alvotech, said in a company pr...

Mavyret Patent Abandonment Does Not Open the Field for Hepatitis C Generics

July 28, 2026 marked eight years of the National Viral Hepatitis Control Program (NVHCP). Launched under the National Health Mission, the program aims to eliminate Hepatitis C from...

<![CDATA[Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb]]&...

<![CDATA[FDA Approves Imaavy for Warm Autoimmune Hemolytic Anemia in Patients Aged 12 and Older]]>

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde. 

AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies

ADARx has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing clinical trials of a range of next-gen small interfering RNA medicines.

<![CDATA[Licensing Roundup: Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License’s Sentivera...